Our studies highlight the mechanism by which these SL molecules inhibit tumor promotion by reducing TPA-induced NF-κB activity and in regulating several downstream players involved in cell cycle progression, apoptosis, and tumor invasion. The gene discussed is NFKB1; the disease is neoplasm.